Copyright
©The Author(s) 2019.
World J Clin Pediatr. Jan 22, 2019; 8(1): 1-14
Published online Jan 22, 2019. doi: 10.5409/wjcp.v8.i1.1
Published online Jan 22, 2019. doi: 10.5409/wjcp.v8.i1.1
Study | Location | Design | Treatment regimen | Vitamin D levels2 | Treatment duration3 | Cumulative dose | Disease activity4 | ||
Before | After | ||||||||
Wingate, 2014 | 83 (CD) | Canada | RCT | A: 400 IU/d D3; B: 2000 IU/d D3 | 24 ± 7.9; A: 26 ± 9.2; B: 22 ± 6.8 | A: 28.8 ± 9.2 (3 mo), 28 ± 8.6 (6 mo); B: 34 ± 10 (3 mo), 34.4 ± 10.4 (6 mo) | 26 (183) | A: 73200 IU; B: 366000 IU | A: < 10:83 B: < 10:88 |
Pappa, 2012 | 71 (IBD) | United States | RCT | A: 2000 IU/d D2; B: 2000 IU/d D3; C: 50000 IU/wk D2 | A: 16.1 ± 1; B: 14.7 ± 0.8; C: 51.3 ± 1 | A:25.7 ± 2.2 (6 wk); B:31.5 ± 1.9 (6 wk); C: 40.8 ± 2.6 (6 wk) | 6 (42) | A: 84000 IU; B: 84000 IU; C: 300000 IU | A: <10:54; B: <10:54; C: <10:78 |
Simek, 2016 | 32 (IBD) | United States | RCT | A: 5000 IU/10 kg/wk D3; B: 1000 IU/10 kg/wk D3 | A: 24 ± 7; B: 23.7 ± 8.5 | A: 41.5 ± 9.6 (8 wk), 30.8 ± 4.2 (12 wk); B: 49.2 ± 13.6 (8 wk), 35.1 ± 8.4 (12 wk) | 6 (42) | A: up to 150000 IU; B: up to 150000 IU | Unknown |
Shepherd, 2015 | 76 (IBD) | Australia | Retrospective | < 3 yr: 200000 IU D3; 3-12 yr: 400000 IU D3; > 12 yr: 800000 IU D3 | 16.4 ± 3.2 | 58.4 ± 20.8 (1 mo); 34.8 ± 11.2 (3 mo); 27.6 ± 12.4 (6 mo) | Single dose | < 3 yr: 200000 IU D3; 3-12 yr: 400000 IU D3; > 12 yr: 800000 IU D3 | 10 (0-47.5) 0 mo; 2.5 (0-85) 6 mo |
Santucci, 2014 | 61 (IBD) | United States | Retrospective | A: no treatment; B: 400 IU/d; C: 600-1200 IU/d; D: 2000 IU/d or 50000 IU/wk | 45% < 30 ng/mL (baseline); 50% < 30 ng/mL; 25% < 30 ng/mL; 88% < 30 ng/mL | Unknown | Unknown | Unknown |
- Citation: Rigterink T, Appleton L, Day AS. Vitamin D therapy in children with inflammatory bowel disease: A systematic review. World J Clin Pediatr 2019; 8(1): 1-14
- URL: https://www.wjgnet.com/2219-2808/full/v8/i1/1.htm
- DOI: https://dx.doi.org/10.5409/wjcp.v8.i1.1